Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.

The American Cancer Society expects 600,920 Americans to die from cancer this year, but Ziopharm Oncology Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) aim to lower that figure. Both of these clinical-stage biotechs are developing some exciting new treatment options, and success could lead to monstrous gains over the long run.

Here's a closer look at what they've got cooking in clinical trials to see which stock is a better pick at the moment.

Image source: Getty Images.

Source: Fool.com